The Cancer Research Institute (CRI) and Stand Up To Cancer (SU2C), in partnership with the American Association for Cancer Research (AACR), have issued a call for letters of intent from scientists and clinical investigators interested in forming the SU2C-CRI Cancer Immunology Translational Research Dream Team.<\/p>\n\n\n\n
As part of this program, CRI and SU2C will provide up to $6 million over three years to fund a translational cancer research project that addresses treatment, control, and prevention of cancer by immunology-based therapeutic approaches, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators. The project must be designed to accelerate the application of new diagnostic or therapeutic agents to the clinic within 2-3 years.<\/p>\n\n\n\n
As the only nonprofit organization with 60 years of leadership in the field of tumor immunology, the Cancer Research Institute has played an integral role in shaping the vision for the field since its earliest years, and has provided the foundation for today\u2019s emerging class of effective cancer immunotherapies.<\/p>\n\n\n\n
\u201cThrough this partnership, Stand Up To Cancer and CRI will leverage one another\u2019s resources to obtain greater impact than either organization could have achieved alone,\u201d says Jill O\u2019Donnell-Tormey, PhD, CEO and director of scientific affairs for CRI. \u201cMatched support from SU2C means CRI\u2019s donors are getting more than twice the return on their charitable investment in our mission, and that\u2019s extremely valuable at a time when funding for translational cancer immunology research is scarce.\u201d<\/p>\n\n\n\n
O\u2019Donnell-Tormey also anticipates that the partnership will help to raise public awareness of the potential for immunotherapy to transform the treatment of all cancers. \u201cThrough SU2C\u2019s television broadcasts and public service announcements, more people will learn about cancer immunotherapy and the work of the Cancer Research Institute, and that\u2019s going to be very good for the field and, ultimately, for cancer patients.\u201d<\/p>\n\n\n\n
Stand Up To Cancer launched the first cancer research Dream Teams in May 2009 in an effort to unify leading scientists from various disciplines and focus their efforts on shared objectives. Six Dream Teams have already begun work in breast and other women\u2019s cancers, pancreatic cancer, genetic studies, and diagnostics. SU2C recently announced calls to form Dream Teams focused on melanoma and prostate cancer.<\/p>\n\n\n\n
\u201cWe are working with SU2C and AACR to establish the Joint Scientific Advisory Committee (JSAC) that will oversee the Immunology Dream Team selection process, and are confident that the research project most likely to have the greatest impact on cancer patient health will be selected,\u201d O\u2019Donnell-Tormey says.<\/p>\n\n\n\n
CRI\u2019s representative on the JSAC is Giorgio Trinchieri, MD, director of the Cancer and Inflammation Program and chief of the Laboratory of Experimental Immunology at the Center for Cancer Research, National Cancer Institute, National Institutes of Health, and associate director for basic science at the Trans-NIH Center for Human Immunology. Trinchieri, who is serving as JSAC co-chair, is a longtime member of the CRI Scientific Advisory Council and sits on the CRI Postdoctoral Fellowship Review Committee.<\/p>\n\n\n\n
\u201cThe recent advances in many different aspects of immunotherapy\u2014from the elicitation of the patients\u2019 own immunological response against tumors either by active vaccination or by the removal of immunological brakes, to the successful use of adoptive cell transfer therapy protocols\u2014has clearly demonstrated that immunity can be harnessed for a successful tumor treatment,\u201d says Trinchieri, \u201cand that rational combination of novel immunotherapies with classical chemo or radiotherapy or molecularly targeted therapies likely offers the highest chance of success for the complete cure of many cancers.\u201d<\/p>\n\n\n\n
According to Trinchieri, an initiative such as the SU2C-CRI Cancer Immunology Translational Research Dream Team offers a unique opportunity to tackle successfully the complexity of the different fields of research of tumor microenvironment, molecular genetics, metabolic response, and immunology that need to be combined in order to rapidly make available effective immunotherapies to cancer patients.<\/p>\n\n\n\n
\u201cSuch an accomplishment would indeed fulfill the dream of CRI\u2019s founder Mrs. Helen Coley Nauts and of Dr. Lloyd Old to use immunology for the treatment, control, and prevention of cancer beyond what surgery and conventional therapy can accomplish,\u201d Trinchieri says.<\/p>\n\n\n\n